Product Intro:
Glenstim Peg 6mg contains Pegfilgrastim, a pegylated recombinant human granulocyte colony-stimulating factor (PEG-G-CSF), designed to stimulate the bone marrow to produce neutrophils. It is primarily used in cancer patients to combat neutropenia induced by chemotherapy.
Uses:
Glenstim Peg is indicated for the following uses:
-
Prevention of chemotherapy-induced neutropenia
-
Reducing the incidence of febrile neutropenia in cancer patients
-
Supporting bone marrow recovery post stem cell transplantation
-
Enhancing white blood cell production in myelosuppressive therapies
-
Reducing the duration of neutropenia in cytotoxic chemotherapy
-
Decreasing the risk of infection due to low neutrophil count
Storage Instructions:
-
Store in a refrigerator at 2°C to 8°C
-
Do not freeze
-
Protect from light
-
Do not shake the syringe
-
Keep out of reach of children
How it Works (Mechanism of Action):
Pegfilgrastim is a pegylated form of filgrastim (G-CSF) that binds to specific receptors on hematopoietic cells, stimulating the proliferation, differentiation, and activation of neutrophil progenitor cells. The pegylation increases the half-life, allowing for a single-dose regimen per chemotherapy cycle.
Side Effects:
Common Side Effects:
-
Bone pain
-
Muscle aches
-
Headache
-
Injection site redness or swelling
-
Fatigue
Severe Side Effects:
-
Splenic rupture (rare but serious)
-
Acute respiratory distress syndrome (ARDS)
-
Allergic reactions (anaphylaxis)
-
Capillary leak syndrome
-
Leukocytosis (excess WBCs)
Dosage (Typical Recommended Dose):
-
Adults: A single 6 mg subcutaneous injection once per chemotherapy cycle
-
Administered approximately 24 hours after chemotherapy
Method of Administration:
-
Subcutaneous injection only
-
Administer in the upper arm, thigh, or abdomen
-
Should be given by a healthcare professional or self-administered under medical guidance
Precautions:
-
Monitor for signs of splenomegaly or spleen rupture
-
Use with caution in patients with sickle cell disease
-
Not recommended in pediatric patients without specialist consultation
-
Inform your doctor if pregnant or breastfeeding
-
Ensure patient is not hypersensitive to filgrastim or PEG derivatives
Drug Interactions:
-
No major drug-drug interactions known, but inform your doctor about all concurrent medications
-
Use caution when combined with lithium, which may also stimulate neutrophil production
Allergies:
-
Contraindicated in individuals with known hypersensitivity to Pegfilgrastim or E. coli-derived proteins
-
Symptoms may include rash, itching, dizziness, or difficulty breathing
Overdose Information:
-
Overdose may cause excessive leukocytosis
-
Monitor complete blood count (CBC) and provide supportive care as needed
-
Seek immediate medical attention in case of suspected overdose
Missed Dose Instructions:
-
If a dose is missed, consult your healthcare provider immediately
-
Do not administer close to the next chemotherapy cycle unless advised
Additional Notes:
-
Should not be used within 14 days before or 24 hours after chemotherapy
-
Regular monitoring of blood cell counts is essential during therapy
-
Patients should be educated on signs of infection and when to seek medical help
Product Intro:
Glenstim Peg 6mg contains Pegfilgrastim, a pegylated recombinant human granulocyte colony-stimulating factor (PEG-G-CSF), designed to stimulate the bone marrow to produce neutrophils. It is primarily used in cancer patients to combat neutropenia induced by chemotherapy.
Uses:
Glenstim Peg is indicated for the following uses:
-
Prevention of chemotherapy-induced neutropenia
-
Reducing the incidence of febrile neutropenia in cancer patients
-
Supporting bone marrow recovery post stem cell transplantation
-
Enhancing white blood cell production in myelosuppressive therapies
-
Reducing the duration of neutropenia in cytotoxic chemotherapy
-
Decreasing the risk of infection due to low neutrophil count
Storage Instructions:
-
Store in a refrigerator at 2°C to 8°C
-
Do not freeze
-
Protect from light
-
Do not shake the syringe
-
Keep out of reach of children
How it Works (Mechanism of Action):
Pegfilgrastim is a pegylated form of filgrastim (G-CSF) that binds to specific receptors on hematopoietic cells, stimulating the proliferation, differentiation, and activation of neutrophil progenitor cells. The pegylation increases the half-life, allowing for a single-dose regimen per chemotherapy cycle.
Side Effects:
Common Side Effects:
-
Bone pain
-
Muscle aches
-
Headache
-
Injection site redness or swelling
-
Fatigue
Severe Side Effects:
-
Splenic rupture (rare but serious)
-
Acute respiratory distress syndrome (ARDS)
-
Allergic reactions (anaphylaxis)
-
Capillary leak syndrome
-
Leukocytosis (excess WBCs)
Dosage (Typical Recommended Dose):
-
Adults: A single 6 mg subcutaneous injection once per chemotherapy cycle
-
Administered approximately 24 hours after chemotherapy
Method of Administration:
-
Subcutaneous injection only
-
Administer in the upper arm, thigh, or abdomen
-
Should be given by a healthcare professional or self-administered under medical guidance
Precautions:
-
Monitor for signs of splenomegaly or spleen rupture
-
Use with caution in patients with sickle cell disease
-
Not recommended in pediatric patients without specialist consultation
-
Inform your doctor if pregnant or breastfeeding
-
Ensure patient is not hypersensitive to filgrastim or PEG derivatives
Drug Interactions:
-
No major drug-drug interactions known, but inform your doctor about all concurrent medications
-
Use caution when combined with lithium, which may also stimulate neutrophil production
Allergies:
-
Contraindicated in individuals with known hypersensitivity to Pegfilgrastim or E. coli-derived proteins
-
Symptoms may include rash, itching, dizziness, or difficulty breathing
Overdose Information:
-
Overdose may cause excessive leukocytosis
-
Monitor complete blood count (CBC) and provide supportive care as needed
-
Seek immediate medical attention in case of suspected overdose
Missed Dose Instructions:
-
If a dose is missed, consult your healthcare provider immediately
-
Do not administer close to the next chemotherapy cycle unless advised
Additional Notes:
-
Should not be used within 14 days before or 24 hours after chemotherapy
-
Regular monitoring of blood cell counts is essential during therapy
-
Patients should be educated on signs of infection and when to seek medical help
